{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:01:38Z","timestamp":1749268898412,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02643-y","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:11:04Z","timestamp":1749183064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug treatment options of high-risk biochemically recurrent prostate cancer based on efficacy and safety: a systematic review and Bayesian network analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"1","key":"2643_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA A Cancer J Clin"},{"issue":"17","key":"2643_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"2643_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","volume":"109","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109(1):32\u20139.","journal-title":"BJU Int"},{"issue":"4","key":"2643_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433.","journal-title":"JAMA"},{"issue":"11","key":"2643_CR5","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1002\/cncr.10977","volume":"95","author":"PA Kupelian","year":"2002","unstructured":"Kupelian PA, Buchsbaum JC, Elshaikh M, et al. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer. 2002;95(11):2302\u20137.","journal-title":"Cancer"},{"issue":"3","key":"2643_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12094-016-1538-5","volume":"19","author":"F Casas","year":"2017","unstructured":"Casas F, Henr\u00edquez I, Bejar A, et al. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study. Clin Transl Oncol. 2017;19(3):373\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"2643_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/pros.23967","volume":"80","author":"ND Shore","year":"2020","unstructured":"Shore ND, Antonarakis ES, Cookson MS, et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate. 2020;80(6):527\u201344.","journal-title":"Prostate"},{"issue":"11","key":"2643_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","volume":"22","author":"F Saad","year":"2021","unstructured":"Saad F, Efstathiou E, Attard G, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021;22(11):1541\u201359.","journal-title":"Lancet Oncol"},{"issue":"15","key":"2643_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2643_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"2643_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.euo.2021.04.008","volume":"4","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Mota JM, Lacuna K, et al. Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503). Eur Urol Oncol. 2021;4(4):543\u201352.","journal-title":"Eur Urol Oncol"},{"key":"2643_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5454727","volume":"2022","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Alumkal JJ, Szmulewitz RZ, et al. Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer. S Goyal Prostate Cancer. 2022;2022:1\u201312.","journal-title":"S Goyal Prostate Cancer"},{"key":"2643_CR13","unstructured":"Aggarwal R, Heller G, Hillman D W et al. PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol. 2024."},{"issue":"16","key":"2643_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, De Almeida LM, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365.","journal-title":"N Engl J Med."},{"issue":"372","key":"2643_CR15","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021(372): n71.","journal-title":"BMJ"},{"key":"2643_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"5","key":"2643_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"2643_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","volume":"17","author":"C Carrie","year":"2016","unstructured":"Carrie C, Hasbini A, De Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747\u201356.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2643_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740\u20139.","journal-title":"Lancet Oncol"},{"issue":"28","key":"2643_CR20","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1200\/JCO.2005.01.2906","volume":"23","author":"P Zhou","year":"2005","unstructured":"Zhou P, Chen M-H, McLeod D, et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23(28):6992\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2643_CR21","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/jnci\/djg043","volume":"95","author":"AV D\u2019Amico","year":"2003","unstructured":"D\u2019Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. JNCI J Nat Cancer Inst. 2003;95(18):1376\u201383.","journal-title":"JNCI J Nat Cancer Inst"},{"issue":"32","key":"2643_CR22","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2643_CR23","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"15","key":"2643_CR24","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408\u201318.","journal-title":"N Engl J Med"},{"issue":"18","key":"2643_CR25","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.22.02394","volume":"41","author":"MJ Morris","year":"2023","unstructured":"Morris MJ, Heller G, Hillman DW, et al. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023;41(18):3352\u201362.","journal-title":"J Clin Oncol"},{"issue":"10323","key":"2643_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","journal-title":"Lancet"},{"issue":"6","key":"2643_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.22.01662","volume":"41","author":"PT Tran","year":"2023","unstructured":"Tran PT, Lowe K, Tsai H-L, et al. Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial. J Clin Oncol. 2023;41(6):1307\u201317.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2643_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/COC.0b013e31829e17db","volume":"38","author":"WC Jackson","year":"2015","unstructured":"Jackson WC, Johnson SB, Feng FY, et al. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015;38(4):367\u201372.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"2643_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.eururo.2017.07.026","volume":"73","author":"N Fossati","year":"2018","unstructured":"Fossati N, Karnes RJ, Colicchia M, et al. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol. 2018;73(3):436\u201344.","journal-title":"Eur Urol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02643-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:11:07Z","timestamp":1749183067000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02643-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2643"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02643-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (name of institute\/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to manuscript submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}